KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Restructuring Costs (2016 - 2026)

Biogen has reported Restructuring Costs over the past 13 years, most recently at $7.9 million for Q1 2026.

  • For Q1 2026, Restructuring Costs fell 77.62% year-over-year to $7.9 million; the TTM value through Mar 2026 reached $21.2 million, down 60.74%, while the annual FY2025 figure was $48.6 million, 60.93% up from the prior year.
  • Restructuring Costs for Q1 2026 was $7.9 million at Biogen, up from $6.6 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $900.0 million in Q2 2022 and troughed at -$700000.0 in Q2 2025.
  • A 5-year average of $68.5 million and a median of $7.4 million in 2025 define the central range for Restructuring Costs.
  • Biggest five-year swings in Restructuring Costs: soared 1311.43% in 2023 and later plummeted 110.61% in 2025.
  • Year by year, Restructuring Costs stood at $7.0 million in 2022, then soared by 1311.43% to $98.8 million in 2023, then tumbled by 94.64% to $5.3 million in 2024, then rose by 24.53% to $6.6 million in 2025, then grew by 19.7% to $7.9 million in 2026.
  • Business Quant data shows Restructuring Costs for BIIB at $7.9 million in Q1 2026, $6.6 million in Q4 2025, and $7.4 million in Q3 2025.